Daiichi Sankyo Company, Ltd (TSE: 4568) has appointed Hiroyuki Okuzawa, 62, to succeed Sunao Manabe, DVM, Ph.D. as Chief ...

Japanese healthcare firm Daiichi Sankyo Co., Ltd (DSKYF.PK) announced Friday the appointment of Hiroyuki Okuzawa as Chief Executive ...

The Japanese pharma had one asset rejected by the FDA and withdrew a regulatory application for another, but already this ...

Jefferies analyst Stephen Barker maintained a Buy rating on Daiichi Sankyo Company (DSKYF – Research Report) on January 19 and set a price ...

DXd, significantly improved median progression-free survival in a Phase III study but failed to do so for overall survival.

Daiichi Sankyo shares rose sharply after the U.S. Food and Drug Administration approved its breast cancer drug Datroway. Shares were recently 8.7% higher at 4,437 yen, equivalent to $28.39, on Monday ...

1 Day DSKYF 10.11% DJIA 1.65% S&P 500 1.83% Health Care/Life Sciences 0.69% ...

Daiichi Sankyo Company, Ltd (TSE: 4568) announced today that it will pay Glycotope $132.5 million to acquire intellectual ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Because of these effects, understanding the out-of-pocket costs for SGLT-2 inhibitors is essential. However, estimates for out-of-pocket costs are limited with no nationally representative or ...

NEW YORK – AstraZeneca and Daiichi Sankyo last week said they have voluntarily withdrawn an application seeking approval in the EU for their TROP2-directed antibody-drug conjugate (ADC) datopotamab ...

In the Phase 3 TROPION-Breast01 trial, AstraZeneca and Daiichi compared datopotamab deruxtecan to chemotherapy in patients whose tumors can’t be removed by surgery or have spread outside the breast ...